PHASE I CLINICAL TRIAL OF 17-ALLYLAMINO-17-DEMETHOXY-GELDANAMYCIN (KOS-953)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Phase I, open-label, dose excalating trial in patients with advanced multiple myeloma. The primary objective is to determine the MTD of KOS-953 (17-AAG) when administered in combination with bortezomib (BZ) to patients with relapsed or relapsed/refractory multiple myeloma on Day 1, 4 8 and 11 every three weeks.